Literature DB >> 17870068

Uveal melanoma expression of indoleamine 2,3-deoxygenase: establishment of an immune privileged environment by tryptophan depletion.

Peter W Chen1, Jessamee K Mellon, Elizabeth Mayhew, Shixuan Wang, Yu Guang He, Nick Hogan, Jerry Y Niederkorn.   

Abstract

The enzyme indoleamine 2,3-dioxygenase (IDO) catalyzes degradation of tryptophan, an essential amino acid required for lymphocyte activation and proliferation. Many tumors express IDO which implies that it acts as a mechanism to evade T cell-mediated immune attack, and also to establish an immunosuppressive tumor microenvironment. The purpose of this study was to determine whether primary and metastatic uveal melanoma expressed the IDO gene and whether uveal melanoma cells could deplete tryptophan. In situ expression of IDO in primary uveal melanoma from tumor bearing eyes and metastatic uveal melanoma liver tissues was determined by immunohistostaining with IDO-specific antibody. Reverse transcription PCR was used to assess IDO gene transcription by primary and metastatic uveal melanoma cell lines. IDO protein expression was determined by Western blot of uveal melanoma cell protein lysate. IDO catalytic activity was assessed by measuring the presence of kynurenine, a product generated by tryptophan degradation, in uveal melanoma culture supernatants. Primary uveal melanoma from tumor-bearing eyes and metastatic uveal melanoma from the liver did not express IDO in situ. IDO was not constitutively expressed in either primary or metastatic uveal melanoma cell lines. However, stimulation of primary and metastatic uveal melanoma cell cultures with interferon-gamma (IFN-gamma) universally upregulated both IDO gene and protein expression. Culture supernatants from IFN-gamma treated primary and metastatic uveal melanoma cell cultures contained elevated levels of kynurenine. Addition of the IDO inhibitor 1-methyl dl-tryptophan significantly diminished kynurenine levels in IFN-gamma treated uveal melanoma cell cultures. The results from this study suggest that IFN-gamma inducible IDO upregulation by primary and metastatic uveal melanoma may generate a local immune privileged microenvironment to promote escape from T cell-mediated immune surveillance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17870068      PMCID: PMC2695208          DOI: 10.1016/j.exer.2007.07.014

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  53 in total

Review 1.  Cellular and molecular mechanisms of liver tolerance.

Authors:  Ian N Crispe; Matthew Giannandrea; Ingo Klein; Beena John; Bradford Sampson; Sherry Wuensch
Journal:  Immunol Rev       Date:  2006-10       Impact factor: 12.988

2.  High avidity melanoma-reactive cytotoxic T lymphocytes are efficiently induced from peripheral blood lymphocytes on stimulation by peptide-pulsed melanoma cells.

Authors:  N Gervois; N Labarriere; S Le Guiner; M C Pandolfino; J F Fonteneau; Y Guilloux; E Diez; B Dreno; F Jotereau
Journal:  Clin Cancer Res       Date:  2000-04       Impact factor: 12.531

3.  Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients.

Authors:  Georg Weinlich; Christian Murr; Laura Richardsen; Christiana Winkler; Dietmar Fuchs
Journal:  Dermatology       Date:  2007       Impact factor: 5.366

4.  Structure--function relationships of rat hepatic tryptophan 2,3-dioxygenase: identification of the putative heme-ligating histidine residues.

Authors:  R Dick; B P Murray; M J Reid; M A Correia
Journal:  Arch Biochem Biophys       Date:  2001-08-01       Impact factor: 4.013

5.  Indoleamine 2,3-dioxygenase (IDO) is involved in promoting the development of anterior chamber-associated immune deviation.

Authors:  Xuan Chen; Lan Liu; Peizeng Yang; Changyou Wu; Haoli Jin; Lin Xing; Bing Li; Hongyan Zhou; Xiangkun Huang; Lianxiang Zhu
Journal:  Immunol Lett       Date:  2006-09-25       Impact factor: 3.685

6.  Human placental indoleamine 2,3-dioxygenase: cellular localization and characterization of an enzyme preventing fetal rejection.

Authors:  Y Kudo; C A Boyd
Journal:  Biochim Biophys Acta       Date:  2000-01-03

7.  Regulation of indoleamine 2,3-dioxygenase, the first enzyme in UV filter biosynthesis in the human lens. Relevance for senile nuclear cataract.

Authors:  O Takikawa; T Littlejohn; J F Jamie; M J Walker; R J Truscott
Journal:  Adv Exp Med Biol       Date:  1999       Impact factor: 2.622

Review 8.  IFN-gamma activated indoleamine 2,3-dioxygenase activity in human cells is an antiparasitic and an antibacterial effector mechanism.

Authors:  W Däubener; C R MacKenzie
Journal:  Adv Exp Med Biol       Date:  1999       Impact factor: 2.622

9.  Adoptive T cell immunotherapy of human uveal melanoma targeting gp100.

Authors:  R P Sutmuller; L R Schurmans; L M van Duivenvoorde; J A Tine; E I van Der Voort; R E Toes; C J Melief; M J Jager; R Offringa
Journal:  J Immunol       Date:  2000-12-15       Impact factor: 5.422

Review 10.  The role of indoleamine 2,3-dioxygenase in transplantation.

Authors:  Ursula Hainz; Birgit Jürgens; Andreas Heitger
Journal:  Transpl Int       Date:  2007-02       Impact factor: 3.782

View more
  24 in total

1.  Identification of an Immunogenic Subset of Metastatic Uveal Melanoma.

Authors:  Luke D Rothermel; Arvind C Sabesan; Daniel J Stephens; Smita S Chandran; Biman C Paria; Abhishek K Srivastava; Robert Somerville; John R Wunderlich; Chyi-Chia R Lee; Liqiang Xi; Trinh H Pham; Mark Raffeld; Parthav Jailwala; Manjula Kasoji; Udai S Kammula
Journal:  Clin Cancer Res       Date:  2015-12-28       Impact factor: 12.531

Review 2.  Ocular diseases: immunological and molecular mechanisms.

Authors:  Jing Song; Yi-Fei Huang; Wen-Jing Zhang; Xiao-Fei Chen; Yu-Mian Guo
Journal:  Int J Ophthalmol       Date:  2016-05-18       Impact factor: 1.779

Review 3.  Immune escape mechanisms of intraocular tumors.

Authors:  Jerry Y Niederkorn
Journal:  Prog Retin Eye Res       Date:  2009-06-27       Impact factor: 21.198

Review 4.  Immunotherapy for uveal melanoma.

Authors:  Dae Won Kim; Jaime Anderson; Sapna P Patel
Journal:  Melanoma Manag       Date:  2016-05-19

Review 5.  Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.

Authors:  Kimberly M Komatsubara; Richard D Carvajal
Journal:  Curr Oncol Rep       Date:  2017-07       Impact factor: 5.075

Review 6.  Biology of advanced uveal melanoma and next steps for clinical therapeutics.

Authors:  Jason J Luke; Pierre L Triozzi; Kyle C McKenna; Erwin G Van Meir; Jeffrey E Gershenwald; Boris C Bastian; J Silvio Gutkind; Anne M Bowcock; Howard Z Streicher; Poulam M Patel; Takami Sato; Jeffery A Sossman; Mario Sznol; Jack Welch; Magdalena Thurin; Sara Selig; Keith T Flaherty; Richard D Carvajal
Journal:  Pigment Cell Melanoma Res       Date:  2014-09-01       Impact factor: 4.693

7.  Molecular profiling of primary uveal melanomas with tumor-infiltrating lymphocytes.

Authors:  Pierre L Triozzi; Lynn Schoenfield; Thomas Plesec; Yogen Saunthararajah; Raymond R Tubbs; Arun D Singh
Journal:  Oncoimmunology       Date:  2014-10-31       Impact factor: 8.110

8.  PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro.

Authors:  Wanhua Yang; Peter W Chen; Haochuan Li; Hassan Alizadeh; Jerry Y Niederkorn
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-02-22       Impact factor: 4.799

9.  The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer.

Authors:  Yan-Fang Gao; Rui-Qing Peng; Jiang Li; Ya Ding; Xing Zhang; Xiao-Jun Wu; Zhi-Zhong Pan; De-Sen Wan; Yi-Xin Zeng; Xiao-Shi Zhang
Journal:  J Transl Med       Date:  2009-08-20       Impact factor: 5.531

10.  Bioinformatic Analysis Reveals Central Role for Tumor-Infiltrating Immune Cells in Uveal Melanoma Progression.

Authors:  Mieszko Lachota; Anton Lennikov; Karl-Johan Malmberg; Radoslaw Zagozdzon
Journal:  J Immunol Res       Date:  2021-06-11       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.